Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.68 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.66 |
| ▸ | THRA | P10827 | 5/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216221 | 0.92 | THRB (0.69) | THRBP2RX7THRAABCB11 | |
| SCHEMBL6217901 | 0.90 | THRB (0.63) | THRBP2RX7THRAABCB11 | |
| SCHEMBL6214554 | 0.87 | THRB (0.66) | THRBP2RX7THRAABCB11 | |
| SCHEMBL6212729 | 0.87 | THRB (0.65) | THRBP2RX7THRA | |
| SCHEMBL6218084 | 0.86 | THRB (0.66) | THRBP2RX7THRAABCB11 | |
| SCHEMBL6215217 | 0.85 | THRB (0.63) | THRBP2RX7THRA | |
| SCHEMBL6216032 | 0.84 | THRB (0.62) | THRBP2RX7THRA | |
| SCHEMBL6216882 | 0.84 | THRB (0.59) | THRBP2RX7THRA | |
| SCHEMBL6213844 | 0.83 | THRB (0.75) | THRBP2RX7THRA | |
| SCHEMBL6218795 | 0.82 | THRB (0.64) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930107-B2 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-16 | — | — | US | disclosed |
| EP-1088819-B1 | 6-azauracil derivatives as thyroid receptor ligands | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6787652-B1 | LOWERING LIPIDS AND SERUM CHOLESTEROL WITHOUT GENERATING ADVERSE CARDIAC EFFECTS; 4,5-DIHYDRO-3,5-DIOXO-1,2,4-TRIAZINE DERIVATIVES | PFIZER, INC. | 2004-09-07 | — | — | US | disclosed |
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | DOW ROBERT L (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157844-A1 | 6-azauracil derivatives as thyroid receptor ligands | TSHR, THRA, THRB | THRB 3/4885P2RX7 716/4885THRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.